Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) rose 1.8% during trading on Thursday . The company traded as high as $14.80 and last traded at $14.33, with a volume of 153,207 shares. The stock had previously closed at $14.07.

BLCM has been the subject of a number of research reports. Zacks Investment Research lowered Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a research report on Thursday, March 17th. Piper Jaffray Cos. restated a “buy” rating and set a $33.00 price objective (down from $45.00) on shares of Bellicum Pharmacueticals in a research report on Monday, March 14th. SunTrust Banks Inc. began coverage on Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price target for the company. Finally, Jefferies Group reduced their price target on Bellicum Pharmacueticals from $35.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, March 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $28.00.

The firm’s 50-day moving average price is $12.53 and its 200 day moving average price is $11.60. The company’s market cap is $403.68 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, analysts predict that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current fiscal year.

In related news, CTO Kevin M. Slawin sold 55,000 shares of the company’s stock in a transaction dated Friday, April 22nd. The stock was sold at an average price of $11.43, for a total value of $628,650.00. Following the completion of the sale, the chief technology officer now owns 159,206 shares in the company, valued at $1,819,724.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Annemarie Moseley sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total value of $325,000.00. Following the completion of the sale, the chief operating officer now owns 18,486 shares of the company’s stock, valued at approximately $240,318. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley increased its position in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent SEC filing.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.